Safety and exceptional immunogenicity of novel 5T4 viral vectored

vaccination regimes in early stage prostate cancer: a phase I clinical trial

Authors: Federica Cappuccini[1] , Richard Bryant[2,3], Emily Pollock[1], Lucy Carter[1], Clare

Verrill[2,4], Julianne Hollidge[2,3], Ian Poulton[1], Megan Baker[1], Celia Mitton[1], Andrea Baines[1],

Armin Meier[5], Guenter Schmidt[5], Richard Harrop[6], Andrew Protheroe[7], Ruth MacPherson[8],

Steven Kennish[9], Susan Morgan[10], Selena Vigano[11], Pedro Romero[11], Thomas Evans[12],

James W.F. Catto[13], Freddie Hamdy[2,3], Adrian V.S. Hill[1*], Irina Redchenko[1*#]

Affiliations:

[1] The Jenner Institute, University of Oxford, Oxford, UK.

[2] Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.

[3] Department of Urology, Churchill Hospital Oxford University Hospitals NHS Foundation

Trust, Oxford, UK.

[4] Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK.

[5] Definiens GmbH, Munich, Germany.

[6] Oxford Biomedica UK limited, Oxford, UK.

[7] Department of Oncology, Oxford Cancer and Haematology Centre, Churchill Hospital

Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

[8] Department of Radiology, Churchill Hospital Oxford University Hospitals NHS Foundation

Trust, Oxford, UK.

[9] Department of Radiology, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK.

[10] Department of Pathology, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK.

[11] Lausanne University Hospital, Lausanne, Switzerland.

[12] Vaccitech UK limited, Oxford, UK.

[13] Academic Urology Unit, University of Sheffield, Sheffield, UK.

* These authors contributed equally to this work

[#] To whom correspondence should be addressed: irina.redchenko@ndm.ox.ac.uk

Abstract: Prostate cancer (PCa) has been under investigation as a target for antigen-specific

immunotherapies in metastatic disease settings for a decade. However, neither of the two

clinically most developed prostate cancer vaccines, Sipuleucel-T and ProstVac, induce strong

T cell immunity. In this first-in-man study, VANCE, we evaluated a novel vaccination platform

based on two replication-deficient viruses, chimpanzee adenovirus (ChAd) and MVA

(Modified Vaccinia Ankara), targeting the oncofetal self-antigen 5T4 in early stage PCa.

Forty patients, either newly diagnosed with early stage prostate cancer and scheduled for

radical prostatectomy or patients with stable disease on an active surveillance protocol, were

recruited to the study to assess the vaccine safety and T cell immunogenicity. Secondary and

exploratory endpoints included immune infiltration into the prostate, prostate specific antigen

(PSA) change and assessment of phenotype and functionality of antigen-specific T cells.

The vaccine had an excellent safety profile. Vaccination-induced 5T4-specific T cell responses

were measured in blood by *ex vivo* IFN-γ ELISpot and were detected in the majority of patients

with a mean level in responders of 198 spot-forming cells (SFC) per million peripheral blood

mononuclear cells (PBMCs). Flow cytometry analysis demonstrated the presence of both

CD8+ and CD4+ polyfunctional 5T4-specific T cells in the circulation. 5T4-reactive tumour

infiltrating lymphocytes (TILs) were isolated from post-treatment prostate tissue. Some of the

patients had a transient PSA rise 2-8 weeks following vaccination, possibly indicating an

inflammatory response in the target organ. The potent T cell responses elicited support the

evaluation of these vectored vaccine in efficacy trials.

Introduction

PCa is the most common non-cutaneous malignancy in men and the second leading cause of male cancer-related death in the Western world (*1*). If the disease progresses to metastatic castration-resistant prostate cancer (mCRPC), the treatment options are mainly palliative in nature. Two next generation hormonal agents, abiraterone and enzalutamide, have improved treatment of mCRPC, however, resistance to these drugs eventually ensues, with the disease becoming lethal.

Cancer immunotherapy has been evolving over the last decade and may be a viable option for treatment of advanced stage prostate cancer patients. To date, the only therapeutic cancer vaccine to be approved by the US Food and Drug Administration (FDA) is Sipuleucel-T, and is indicated for patients with asymptomatic or minimally symptomatic mCRPC (*2*). This immunotherapy targets the prostate-specific antigen prostatic acid phosphatase (PAP) and is based on autologous peripheral-blood mononuclear cells (including antigen-presenting cells) activated *ex vivo* by cytokines and loaded with a recombinant fusion protein consisting of PAP and granulocyte-macrophage colony-stimulating factor (GM-CSF). The vaccine has shown modest, though statistically significant, efficacy in clinical trials, increasing overall survival in treated patients by four months. However, no effect on time to tumour progression compared to placebo group has been observed and the induced T cell responses appeared weak (*3*).

Another vaccine, ProstVac, has reached a phase III clinical trial (NCT01322490). This vaccine comprises two recombinant viral vectors, replication competent vaccinia and non-replicating fowlpox viruses, each encoding a transgene for PSA. In the phase II randomized placebo-controlled study in patients with metastatic prostate cancer men in the ProstVac group had a significant increase in median overall survival (8.5 months) compared to the control group.

However, T cell immune responses against the vaccine-encoded antigen were very modest (*4*)

and no clinical efficacy was observed in the phase III trial (*5*).

In this current study, we targeted the tumour antigen 5T4 (*6*) using an alternative immunisation

platform based on a chimpanzee adenovirus (ChAd) prime and MVA boost (developed in our

laboratories over a decade ago). This has been shown to be the most powerful approach for

inducing polyfunctional protective T cell responses against antigens from diverse human

pathogens in clinical trials (*7-13*). Preclinical evaluation of this vaccination strategy in murine

prostate cancer models demonstrated its tumour protective efficacy (*14, 15*), thus providing a

rationale for a phase I clinical study. Here we report the results of the first-in-human VANCE

study, evaluating the safety of ChAdOx1-MVA 5T4 vaccine in early stage prostate cancer.

The induction of antigen-specific immune responses in both the blood and the prostate gland,

the effect of low dose cyclophosphamide (CTX) preconditioning on the immune responses

and changes in serum PSA concentration are also reported. Vaccine efficacy assessments are

effectively not possible in this trial design because the selected patient cohort either had a

curative surgical treatment immediately after vaccination, or a subsequent very low risk of

recurrent disease that would require a long follow-up period beyond the duration of this trial

in order to assess any clinical impact of vaccination.

Results

Study participants and safety analysis

Forty patients were enrolled into the VANCE randomised open label phase I study between

26th October 2015 and 19th October 2017, with thirty-nine participants completing the study

treatment and eligible for analysis (Fig. 1). All participants were diagnosed with low- or

intermediate-risk prostate cancer scheduled for radical prostatectomy, or undergoing active

surveillance for low-volume low- or intermediate-risk prostate cancer. Median age, clinical

stage and Gleason score of trial participants are presented in Supplementary Table S1. VANCE

clinical trial design is presented in Supplementary Fig. S1.

ChAdOx1.5T4 and MVA.5T4 vaccines were well tolerated. The majority of reported AEs

related to vaccinations were mild in intensity (92%) and were consistent with side effects

observed for these vectors in other clinical trials. Mild to moderate pain at injection site was

reported by ~50% of patients. The majority of systemic AEs were graded as mild. Among the

common systemic adverse events usually seen post replication-incompetent viral-vectored

vaccines, feverishness, myalgia and fatigue were the most frequently reported, affecting 59%,

70% and 72% of individuals respectively, and usually were resolved within 7 days post-

vaccination.

There were no reported serious adverse events (SAEs) related to the vaccines. The two reported

SAEs, hospital admissions due to an episode of haematemesis and an aortic surgery caused by

ascending aortic aneurysm, were considered unrelated to the vaccines.

Fig. 1. CONSORT flow diagram. Flow chart showing patients participation in VANCE trial

study from screening, enrolment, allocation, follow up and analysis. RP: radical prostatectomy;

AS: active surveillance; CTX: cyclophosphamide.

Vaccine-induced T cell responses in the blood

25 of 39 (64%) patients who completed the vaccination course and were eligible for analysis

mounted 5T4-specific T cell immune responses at one or more blood sampling timepoint, as

measured by *ex vivo* IFN-γ enzyme-linked immunospot (ELISpot) assay, with a mean peak

response of 198 SFC per million PBMCs (Fig. 2A). The detected *ex vivo* 5T4-specific immune

T cell reactivity was attributed to *de novo* induced responses, and only 2 of 39 patients

demonstrated pre-existing 5T4 responses, which increased after vaccination (Fig. 2A). The

standard heterologous regimen (ChAdOx1-MVA-MVA 5T4, 4-week interval) induced an

antigen specific response in 4 of 5 (80%) patients, and the standard homologous regimen

(MVA-MVA-MVA 5T4, 4-week interval) in 4 of 6 (66.7%) patients, with an overall immune

response rate of 73%. In the accelerated heterologous regimen (ChAdOx1-MVA 5T4, 1-week

interval), 17 of 28 (61%) patients showed cellular responses to 5T4 (Fig. 2B). The magnitude

of antigen-specific immune response was not significantly different between standard

homologous and heterologous vaccination regimens, perhaps due to the small number of

patients in these arms. In other indications, the T cell immunogenicity of ChAd-MVA regimens

is consistently higher than that of homologous MVA regimens (*16, 17*). Also, comparable

frequencies of antigen-specific T cells were observed following the standard heterologous and

accelerated heterologous immunisation schedules (Fig. 2B), as has been observed for other

vaccinations such as Ebola (*11*). The CTX preconditioned arms did not show any increase in

the magnitude of circulating T cell responses compared to the vaccine only arms (Fig. 2C).

Importantly, immunisations against the 5T4 protein elicited T cell responses with broad epitope

specificities that changed over time (Fig. 2D).

26 of 39 (67%) patients also mounted 5T4-specific antibody responses as measured by a

relative-quantitative ELISA (*18*). Of note, 5T4 seroconversion occurred in all the patients in

the standard vaccination regimen arms compared to the 46% seroconversion rate in patients

vaccinated according to the accelerated immunisation schedules (Supplementary Table S2).

This finding suggests that a second MVA boost and / or longer intervals between vaccinations

are more favourable for induction of antibody responses to 5T4. There was no correlation

between the induced 5T4-specific antibody and T cell responses (Supplementary Fig. S2).

In order to evaluate T cell immune response kinetics, patients on the same vaccination schedule

were pooled irrespective of other variables (i.e. CTX status pre-treatment, and heterologous or

homologous vaccination). In patients on the standard schedule, the 5T4-specific T cell response

was observed to peaked on two occasions: firstly at 4 weeks after priming, and secondly one

week after the second boost (week 9), at a mean of 54 ± 48 SEM and 72 ± 69 SEM SFC per

million PBMCs respectively (Fig. 3A). This mirrors the immunogenicity of these vectors in

other indications, where responses post-ChAd peak at 2-4 week, and responses post-MVA peak

at one week. A peak T cell response in patients assigned to the accelerated regimen was

observed one week after the boost at a mean of 80 ± 27 SEM in the surgical arm, and 131 ± 85

SEM SFC per million PBMCs in the active surveillance arm (Fig. 3B, C). Following a

contraction phase of the immune response, only weak *ex vivo* responses were detectable at later

time points, likely because effector cells diminish while less activated central memory cells

increase (*10*). Indeed, the repertoire of memory 5T4-specific T cells could be expanded by

short-term *in vitro* culture in the presence of the total 5T4 peptide pool from blood samples

collected 4-6 months after vaccination. Of note, frequencies of expanded 5T4-specific T cells

from blood samples collected prior to vaccination from the same patients were usually much

lower (Fig. 3D).

Fig. 2. *Ex vivo* IFN-γ ELISPOT responses. Vaccine immunogenicity was assessed by *ex vivo* IFN-γ ELISPOT on freshy isolated PBMCs stimulated with 8 pools of overlapping peptides covering the entire 5T4 protein sequence. Values of spot forming cells (SFC) per million PBMCs correspond to the sum of the responses to the single pools. (**A**) Dot plot representing peak responses for each individual patient compared to baseline (BL), pre-vaccination responses. Lines represent mean; the paired t-test *P* value is shown. (**B**) Comparison of peak responses in patients receiving homologous standard vaccination (MVA-MVA-MVA 5T4: MMM), heterologous standard vaccination (ChAdOx1-MVA-MVA 5T4: CMM) and heterologous accelerated vaccination regimes (ChAdOx1-MVA 5T4: CM), irrespective of CTX preconditioning. Lines represent mean; ns: not significant. (**C**) Comparison of peak responses between patients without CTX preconditioning (-CTX) or receiving CTX course (+CTX) for a week before each immunisation, irrespective of vaccination regimen. Lines represent mean; ns: not significant. (**D**) Time-dependent dynamics of cellular responses to individual 5T4 peptide pools (p1 to p8) in 2 representative patients. Arrows represent time points of vaccination. RP: radical prostatectomy; AS: active surveillance; C: ChAdOx1.5T4; M: MVA.5T4.

Fig. 3. Kinetics of 5T4 specific responses. Antigen-specific responses were measured before

vaccination, and at different time points post-vaccination, by *ex vivo* IFN-γ ELISpot assay on

freshy isolated PBMCs. Mean (±SEM) immune responses to 5T4 antigen over time are shown

irrespective of CTX preconditioning: (**A**) in the standard vaccination regimen arms; (**B**) in

surgical patients receiving the accelerated vaccination regimen; and (**C**) in active surveillance

patients receiving the accelerated vaccination regimen. Arrows represent time points of

vaccination. (C/M: ChAdOx1.5T4 or MVA.5T4; C: ChAdOx1.5T4; M: MVA.5T4). (**D**)

Freshy isolated PBMCs from several patients were cultured for 2 weeks in the presence of low

dose hIL-2 and the total 5T4 peptide pool. IFN-γ ELISpot assay was performed on cultured

cells and baseline responses were compared to responses measured at weeks 16 to 24.

Vaccine-induced T cell responses were further characterized using flow cytometry, which is a

less sensitive assay than ELISpot and therefore requires an expansion of the relatively

infrequent 5T4-specific T cells. To this end, PBMCs from several patients collected at baseline

and at various timepoints during the study have been cultured for 12-14 days in presence of the

total 5T4 peptide pool as above. Following *in vitro* stimulation, cell cultures were stained with

fluorochrome-labelled antibodies against CD4+ and CD8+ T cell surface markers and intra-

cellular IFN-γ and TNF-α cytokines characteristic for effector T cells. The gating strategy is

presented in Fig. 4A, and representative plots of IFN-γ+TNF-α+ CD4+ and CD8+ T cells upon

5T4 stimulation are shown in Fig. 4B. 5T4-specific T cell responses in cultured PBMCs were

detected in 15 of 21 (71.4%) patients analysed. Among the responders, 5T4-specific CD4+ T

cell reactivity was found in 10 (66.7%) patients, CD8+ T cell reactivity in 14 (93.3%) patients

and both CD4+ and CD8+ T cell mediated responses in 9 (60%) patients (Fig. 4C). Patients

displaying a post-vaccination positive immune response by flow cytometry also had a low

percentage of both CD4+ and CD8+ polyfunctional T cells detected at baseline (ranges 0.2-

1.8% and 0.01-0.3% respectively). However, these numbers at least doubled after vaccination,

reaching as high as 5.3% and 7.8% of 5T4-specific CD4+ and CD8+ T cells at the peak of the

response (Fig. 4D). The median fold increase of 5T4-specific T cell responses over baseline

values amounted to 4.9 and 4.5 in CD4+ and CD8+ T cells respectively (Fig. 4E). To

corroborate the flow cytometry data on induction of both CD4+ and CD8+ 5T4-specific

responses after short-term *in vitro* stimulation, PBMCs from selected responders have been

retrospectively thawed to perform CD4+ and CD8+ T cell depletions and to test the depleted

cell fractions in parallel with the total PBMCs in an *ex vivo* IFN-γ ELISpot assay

(Supplementary Materials and Methods). As shown in Supplementary Table S3, 9 patients,

including one non-responder, have been analysed to discriminate between CD4+ and CD8+ T

cell responses *ex vivo*. Among the responders, only 4 maintained the response after

freeze/thawing and we could observe CD4+ only mediated, CD8+ only mediated, and both

CD4+ and CD8+ mediated T cell responses, consistent with the results observed by flow

cytometry.

Fig. 4. Flow cytometry analysis of 5T4-specific immune responses induced by vaccination.

Freshly isolated PBMCs were cultured for 2 weeks in the presence of low dose hIL-2 and the

total 5T4 peptide pool to expand relatively infrequent 5T4-specific T cells. Flow cytometric

analysis was performed on cultured cells at different time points, and the percentage of

polyfunctional CD4+ and CD8+ secreting IFN-γ+ and TNF-α+ was calculated by subtracting

background responses (Δ value) and compared to corresponding pre-vaccination values. (**A**)

Representative gating strategy. From left to right, top to bottom: Time – Lymphocytes – Single

cells – Live cells – CD3+ T cells – CD4+ and CD8+ T cells. (**B**) Representative dot plot with

percentages showing CD4+ (top) and CD8+ (bottom) T cells secreting IFN-γ+ and TNF-

α+. (**C**) Percentages of evaluated patients showing a positive response in cultured PBMCs

(grey bar) and relative percentages of positivity for CD4+, CD8+, and both CD4+ and CD8+

among responders (black bars). (**D**) Baseline Δ value percentages of IFN-γ+ and TNF-

α+ CD4+ and CD8+ T cells are compared to corresponding peak Δ value percentages obtained

after vaccination in each individual patient analysed. BL: baseline. (**E**) Fold increase of peak

Δ value percentages over baseline of polyfunctional CD4+ and CD8+ T cells induced by

vaccination are shown. Lines represent median.

Vaccine-induced T cell responses in the prostate

In order to assess the immune response to the vaccine antigen in the target prostate gland, post-

vaccination tissue cores from radical prostatectomy specimens (*19*) and prostate biopsy

samples from active surveillance patients were cultured *in vitro* in the presence of the total 5T4

peptide pool and high dose hIL-2, in order to expand the TILs and enrich them for 5T4-

specificity prior to flow cytometric analysis. Immune cell expansion rates and CD4+ to CD8+

T cell ratios varied between patients, as well as between tissue fragments derived from the

same surgical or biopsy specimen. Representative dot plots of expanded CD4+ and CD8+ T

cells are shown in Fig. 5A. The flow cytometric analysis of TILs was similar to that performed

on cultured PBMCs. 5T4-specific T cell responses could be detected in the prostate samples of

13 of 17 (76.5% response rate) patients analysed. Overall, prostate tissue analysis demonstrated

the presence of 5T4-specific CD4+ T cell reactivity in 8 patients (61.5% of responders), CD8+

T cell reactivity in 11 patients (84.6% of responders) and both CD4+ and CD8+ T cell mediated

responses in 6 patients (46.2% of responders) (Fig. 5B). Percentages of TILs secreting both

IFN-γ and TNF-α measured in 2 representative patients are shown in Fig. 5C, presenting a

comparison between unstimulated and 5T4-stimulated cells.

Fig. 5. Flow cytometry analysis of 5T4 specific immune responses in the prostate tissue.

Post vaccination prostate biopsy samples and radical prostatectomy tissue specimens were

cultured in the presence of high dose hIL-2, and were stimulated with the total 5T4 peptide

pool to expand 5T4-specific T cells derived from the prostate gland. Flow cytometric analysis

was performed on expanded TILs a week after 5T4 stimulation. (**A**) Representative flow dot

plot showing percentages of gated CD4+ and CD8+ TILs obtained from expanded cultures in

different samples. (**B**) Percentages of evaluated samples showing a positive response in

cultured TILs (grey bar) and relative percentages of positivity for the CD4+, CD8+ T cell and

both CD4+ and CD8+ T cell subsets (black bars). (**C**) Percentages of IFN-γ+ and TNF-α+ TILs

(CD4+ and CD8+) in unstimulated cultures (R10: medium only) are compared to the

corresponding 5T4-stimulated cultures (5T4) in 2 representative patients (VAN-807 and VAN-

021). RP: radical prostatectomy; AS: active surveillance.

To evaluate post-treatment changes in the immune cell infiltration using

immunohistochemistry (IHC), tissue sections from archival diagnostic prostate biopsies and

matched post-vaccination on-study biopsies from active surveillance patients were stained with

anti-CD3 and anti-CD8 monoclonal antibody, and densities of CD3+ and CD8+ T cells were

assessed by digital image analysis as previously described (*20*). An increase in CD3+ and

CD8+ T cell density was observed in the post-vaccination prostate gland in some of the

analysed patients. In particular, an increase equal or higher than 1.5-fold in CD3+ and CD8+

T cell density post-treatment was detected in 2 out of 11 patients (18%) and in 4 out of 11

patients (36%) respectively (Supplementary Fig. S3).

IHC analysis was also performed on 12 available radical prostatectomy tissue sections from

patients in Groups 1-4, and both CD3+ and CD8+ T cell infiltration was detected in resection

samples (Supplementary Table S4). However, T cell densities in the prostate gland following

vaccinations could not be reliably compared with the pre-treatment archival biopsy samples

due to technical issues.

Serum PSA changes following vaccination

The serum PSA level is commonly used as a surrogate marker of prostate cancer treatment

efficacy. Potential treatment effects of the vaccine on prostate cancer were assessed by

measuring serum PSA throughout the trial. In the majority of patients in the surgical arms PSA

could only be assessed at a few time points prior to radical prostatectomy, as this intervention

ordinarily causes the PSA to drop to very low or undetectable levels. However, patients on the

active surveillance programme could be followed up for 48 weeks, thus changes in PSA were

monitored in these patients for an extended time period. Fig. 6A shows PSA changes over time

in the 12 patients in the active surveillance arms. Although there was some disparity in the PSA

kinetics between patients, the overall trend showed an unexpected increase in serum PSA

concentration after ChAdOx1.5T4 prime with a peak at week 4, with PSA decreasing to pre-

vaccination levels by week 22 (Fig. 6B). Of note, median peak levels of PSA after vaccination

were significantly higher than median baseline levels (8.25 ng/ml versus 4.16 ng/ml) (Fig. 6C).

Analysis of the maximum PSA change detected at any given time point post-vaccination

demonstrated that 50% of patients experienced an increase of 17- 52% over the baseline. 25%

of patients had ≥100% increase in PSA concentration, and 25% of the patients had a PSA drop

of 12-38% compared to pre-vaccination values (Fig. 6D).

Fig. 6. PSA levels in the active surveillance arms. Serum PSA concentration was measured

throughout the study. Changes in PSA concentration are shown for each individual patient in

the active surveillance arms (**A**), and as mean concentrations±SEM (**B**); Mean PSA levels at

each time point; paired t-test value *P* = 0.02. Arrows represent time points of vaccination. C:

ChAdOx1.5T4; M: MVA.5T4. (**C**) A scatter dot plot graph representing baseline PSA

concentrations compared to corresponding peak concentrations measured post vaccination in

active surveillance patients. Lines represent median; paired t-test value *P*=0.006. (**D**) Waterfall

plot representing the highest PSA change from baseline, expressed as percentage of baseline

value, measured at any given timepoint in patients on the active surveillance arms (patient trial

IDs are given). * represents a systemic immune response to the vaccine measured either by *ex*

vivo IFN-γ ELISpot on freshly isolated PBMCs or flow cytometry on short-term stimulated

PBMCs. # indicates a CD8+ T cell local immune response to the vaccine measured either by

flow cytometry on short-term stimulated TIL cultures or by IHC of post vaccination biopsies

(CD8+ T cell density ≥1.5-fold pre-vaccination biopsies).

The increase of ≥100% in serum PSA levels observed in 3 patients was associated with both

peripheral and local biomarkers of vaccine immunological activity, such as presence of

polyfunctional 5T4-specific CD8+ and CD4+ T cell responses in the blood as measured by *ex*

vivo ELISpot and flow cytometry of short-term cultured PBMCs, expansion of 5T4-specific

polyfunctional T cells from fresh prostate biopsy samples, and a ≥1.5-fold increase in CD8+ T

cell infiltration in post-treatment prostate biopsies compared to baseline (Table 1). T cell

densities, as measured by IHC, of 2 of these 3 patients are shown in Fig. 7, as well as

representative images of IHC staining of the respective prostate biopsies. The TIL and IHC

data for the third patient (VAN-022) were not available as his on-study biopsy was not

performed for clinical reasons.

Patient ID	*Ex vivo* ELISpot Magnitude of peak response (SFC/10^6 PBMCs)	Flow cytometry on cultured PBMCs Peak response fold increase over BL		Flow cytometry on expanded TILs Peak response Δ% of IFN-γ+TNF-α+		IHC Immune infiltration compared to pre-vaccination tissue		PSA levels % of max increase over BL
		CD4+	CD8+	CD4+	CD8+	CD3+	CD8+	
VAN-007	1025	ND	ND	ND	ND		Y	>100
VAN-022	61		8.1	ND	ND	ND	ND	>100
VAN-026	56		10.4		1.64	Y	Y	>100

Table 1. Comparative immune T cell reactivity against the 5T4 antigen as measured by functional assays in the blood and the prostate along with density of T cell infiltration by IHC in 3 selected patients with ≥100% increase in serum PSA. BL – baseline, ND – not done, N - No, Y – Yes.

Fig. 7. T cell infiltration in the prostate. Archival diagnostic prostate biopsies and matched on-study prostate biopsies taken at week 10 from selected patients in the active surveillance arms were tested for T cell infiltration by immunohistochemistry (patient trial IDs are given). Formalin-fixed paraffin-embedded sections were stained with anti-CD3 and anti-CD8 antibodies and cell densities were calculated. (**A**) Comparison of CD3+ (left) and CD8+ (right) T cell densities, expressed as number of cells per mm^2, and (**B**) representative pictures of CD3 and CD8 expression between pre-treatment and post-treatment biopsies in 2 patients who had ≥100% increase in serum PSA levels post-vaccination. Brown regions indicate immunoreactivity. Scale bar is shown (100μm).

Discussion

In this study, the safety profile and immunogenicity of the first-in-man ChAdOx1-MVA

heterologous prime-boost vaccination against the 5T4 tumour antigen, in low- and

intermediate-risk prostate cancer patients, has been evaluated. The rationale for selecting this

patient cohort is that immunotherapy at early stages of the disease should result in greater

clinical benefit, as anti-tumour immune responses need time to develop, and the tumour burden

may be comparatively low, and more accessible to cytotoxic T cells, which are the major

players in anti-tumour protection. An indication of improved benefit in early vaccine therapy

in prostate cancer patients comes from observations in the IMPACT trial, where efficacy of

Sipuleucel-T treatment was particularly pronounced in patients with lower PSA baseline values

(*21*). Another important consideration was the availability of post-vaccination fresh prostate

tissue from biopsy and/or surgical resection specimens, which enabled an assessment of the

effect of vaccination on the target organ in addition to the evaluation of induced immune

responses in the periphery.

The heterologous ChAdOx1-MVA 5T4 vaccine was well tolerated in both the standard and

accelerated regimens. The well-tolerated safety profile was in agreement with previous reports

for these viral vectors (*8, 22, 23*), with only two serious AEs reported over the duration of the

study, both of which were unrelated to the investigational products.

Vaccines induced *de novo* 5T4-specific immunity in each of the eight arms of the study, and

significantly boosted two pre-existing responses. Overall, 64% of patients were found to have

responded to vaccination on at least one time point during the study, with some responses

detected as early as after a single priming immunisation. To our knowledge, this is the best

vaccine-induced immune response rate obtained to date in any clinical trial in prostate cancer

patients measured by *ex vivo* IFN-γ ELISpot assay.

Breaking tolerance to self-antigens by cancer vaccines has been a challenge that has hampered

progress in the cancer immunotherapy field for years, and available information on induced T

cell responses in prostate cancer trials remains sparse. The response rate achieved in the VANCE trial, together with a magnitude of response ranging between 30 and 1025 SFC per million PBMCs, can be considered noteworthy when compared to immunotherapy responses measured in other clinical trials on prostate cancer patients.

The closest comparator for the ChAdOx1-MVA 5T4 vaccine is TroVax, a homologous MVA.5T4 vaccination regimen in the prostate cancer setting (*22*). In the reported phase II trial, 5T4-specific T cell responses were induced in 38% of hormone refractory prostate cancer patients over the course of 11 TroVax immunisations. ProstVac treatment, the poxvirus-based vaccine targeting PSA, induced PSA-specific T cell responses in 57% of patients across six clinical trials. But the magnitude of the response measured 4 weeks after the last immunisation was in the range of 10 to 203 SFU per million PBMCs, with a median response of 30 SFU per million PBMCs. The low T cell responses to the vaccine antigen was interpreted as a reflection of sub-optimal timing for blood sampling and/or trafficking of PSA-specific T cells to the tumour site (*4*). Of note, the highest frequency of responses across 6 ProstVac trials was detected in localized prostate cancer patients. These data suggest that a smaller tumour burden, as well as a generally better immunological fitness of the patients, might positively influence the response rate to cancer vaccines, as observed in the present VANCE study.

The licenced cell-based immunotherapy Sipuleucel-T induced T cell responses to the target antigen, a recombinant fusion protein of PAP and GM-CSF (PA2024), in 48% of treated mCRPC patients compared to 6% in the control group. However, the response rate to the PAP antigen itself was in the range of 6-8% in both treated and control patients (*3*), which suggests that much of T cell reactivity against the recombinant protein may have been directed to the junctional foreign antigens. In another clinical trial, a DNA vaccine encoding PAP and GM-CSF (pTVG-HP) was assessed for immunogenicity in prostate cancer patients with biochemical recurrence. This vaccine only yielded a low response rate of 14% (*24*). A follow-

up study demonstrated that multiple immunisations were necessary for robust responses, as the

majority of patients showed detectable PAP-specific T cells after a course of 6 vaccinations

(*25*). The pTVG-HP vaccine has been evaluated more recently in mCRPC in combination with

anti-PD1 (pembrolizumab) (*26*). The reported T cell responses were likely to be predominantly

CD4+ T cell mediated, as the PAP protein induced much high frequencies of PAP-specific T

cells by IFN-γ ELISpot compared to the PAP peptide antigen. Also, the responses to PAP

peptides were detected after 48-72 hours *in vitro* re-stimulation, in contrast to the standard 18-

hour assay used here. Several other prostate cancer vaccine candidates are currently being

tested in clinical trials in combination with PD-1 checkpoint inhibitors (NCT02325557,

NCT02616185).

RNA-based vaccination approaches have also been evaluated in mCRPC (*27*). The self-

adjuvanted mRNA vaccine CV1903 against 4 prostate antigens induced T cell responses in

55% of patients. These responses were detected after 6 doses of the vaccine and reported as a

cumulative response rate measured by MHC-class I tetramer staining, ICS and IFN-γ ELISpot.

A comparable magnitude of 5T4-specific response was observed across all vaccination

regimens in the VANCE study, with no detectable effect from CTX preconditioning. This

observation was unexpected, as low dose CTX may selectively suppress regulatory T cell

(Treg) number and functionality, without influencing other T cell subsets, and this effect would

have the potential to uncover high-avidity tumour-specific T cells (*28*). However, our

observation of little impact from CTX is corroborated by other studies. For example, depletion

of Tregs with low-dose cyclophosphamide prior to vaccination did not increase immune

responses generated by MVA.5T4 vaccination in metastatic colorectal cancer patients (*29*).

The hypothesis was that CTX might independently improve the efficacy of vaccination without

influencing the immunogenicity of the vaccines. In the majority of VANCE patients, the

induced *ex vivo* T cell responses measured by an IFN-γ ELISpot assay have not been

maintained over time. However, the 5T4-reactive memory cells could be expanded *in vitro* 5

months after the last immunisation.

We observed the presence of vaccine-induced systemic CD8+ or/and CD4+ T cell immune

responses in both *ex vivo* tests and *in vitro* cultured assays. However, vaccine-driven activation

of T cells in the circulation does not always predict local responses within the target organ.

Traditionally, post-vaccination immune responses in the prostate gland have been investigated

exclusively using IHC. As an example, staining of radical prostatectomy specimens after

vaccination with Sipuleucel-T showed an accumulation of CD4+ and CD8+ T cells at the

tumour interface (*30*). Farsaci *et al*. have also showed an increase in CD4+ and CD8+ T cells

within the tumour parenchyma in all patients receiving ProstVac vaccination (*31*). However,

an influx of immune cells into the prostate gland may also be caused by other interventions.

For example, CD4+, and to a lesser extent CD8+, T cell immune infiltration into the prostate

gland has been observed after androgen ablative therapy (*32*). Interestingly, in contrast to

observations seen in other malignancies, a positive correlation between the density of tumour

infiltrating CD8+ T cells and improved clinical outcome remains controversial in prostate

cancer (*33*). On one hand, it has been suggested that in comparison to absent or decreased

immune infiltrates, abundant TILs in the prostate gland is associated with a higher survival

probability (*34*). On the other hand high numbers of TILs within the tumour have been

demonstrated to be predictive of an increased risk of tumour recurrence in patients undergoing

radical prostatectomy, with an expansion of the CD4+ T cell infiltrate being associated with a

poor outcome (*35, 36*). In addition, a strong TIL presence was an independent predictor of

short PSA recurrence-free survival (*37*). More recently, higher levels of primarily CD4+ T cells

and, to a lesser extent, CD8+ T cells, appeared to be associated with a worse distant metastasis-

free survival (*38*). It may therefore be the case that in addition to enumerating T cells in the

prostate tumour, the functional status and tumour specificity of TILs after the vaccination are

important characteristics to analyse. To this end, in parallel with the IHC assessment of

formalin-fixed paraffin-embedded prostate tissue sections, in the VANCE study we obtained

high-quality fresh post-vaccination prostate tissue, in order to study the presence of functional

vaccine-specific T cell responses. We could quantitatively assess 5T4-specific polyfunctional

TILs (i.e. secreting IFN-γ and TNF-α) from the majority of analysed samples. Of note, 11 of

13 (85%) patients demonstrated presence of functional CD8+ T cells, with over 50% of these

patients exhibiting a concomitant CD4+ T cell response. A limitation of our approach is that

the TILs subjected to this functional analysis have been cultured *in vitro*, isolated from the

natural tumour immunosuppressive microenvironment, and so they might have expanded in a

more favourable environment. Another drawback of our analysis is that it was not possible to

compare the immune cell phenotype and function in the prostate gland pre- and post-

vaccination, due to the unavailability of fresh tissue before study treatment. Nevertheless, and

despite the uncertain role of TILs within the prostate gland, we could observe functional

vaccine-specific cytotoxic and T helper cell responses within the prostate gland after

vaccination, as well as T cell infiltration measured by IHC, which might effectively control

prostate cancer development, especially if given in prophylactic vaccine settings.

The presence of 5T4-reactive TILs might also explain the transient increase in PSA levels

observed in active surveillance patients post ChAdOx1.5T4 prime and MVA.5T4 boost

immunisations. This effect might be the result of a vaccine-induced inflammatory response,

and possibly reflects prostate epithelial cell death, following trafficking of 5T4-reactive T cells

to the target organ. Although the observed PSA trends post-vaccination were variable, the

analysed active surveillance patients experienced a significant rise in PSA level, with a peak

observed at week 4 (two weeks after the MVA.5T4 boost). Although the PSA in almost all

patients had normalised to pre-vaccination values by the end of the study, the transient PSA

increase significantly exceeded the physiological variations of PSA in several patients.

Interestingly, a PSA flare phenomenon followed by dramatic clinical and biochemical

responses has been observed after treatment with radium-233 in an extensively pre-treated

metastatic prostate cancer (*39*). Similarly, mCRPC patients treated with chemotherapy

experienced an initial increase in serum PSA, followed by a decrease of at least 50% when

compared to baseline (*40*). PSA dynamics have also been analysed after brachytherapy, and

mechanisms behind the observed "PSA bounce" have been evaluated (*41*). The "PSA bounce"

measured in the brachytherapy study could not be explained by the effect of radiation alone as

it invariably occurred after the isotope had decayed. Therefore, the phenomenon was attributed

to the differential immune response to the tumour coupled with the therapeutic effect of

radiation, as suggested by the strong T cell infiltration detected within the tumours by IHC

analysis of the tissue after therapy. Patients who experienced a PSA bounce had higher

densities of CD3+ and CD8+ T cells within the tumour, and this might have contributed to both

the PSA increase and the improved clinical outcomes observed. These findings are consistent

with our hypothesis that the temporary rise in serum PSA observed in VANCE patients may

have been caused by the local T cell reactivity induced by vaccination. In fact, the finding of a

PSA bounce can be part of so-called tumour pseudoprogression following immunotherapeutic

interventions (*42*).

In conclusion, the heterologous ChAdOx1-MVA 5T4 vaccination regimen in early stage

prostate cancer was found to be both safe and immunogenic, with the majority of prostate

cancer patients enrolled in this trial mounting *ex vivo* T cell responses to the vaccine-encoded

tumour-associated antigen 5T4. Immune responses mediated by polyfunctional CD8+ and

CD4+ T cells could be detected following vaccination *ex vivo* in the blood, and following *in*

vitro culture of cells obtained from prostate tissue. The transient rise in serum PSA observed

post vaccination, which significantly exceeded physiological variation in some patients,

supports a possible vaccination effect within the prostate gland.

It remains to be seen if the vaccination strategy presented herein can be effective in later-stage

prostate cancer therapeutic settings, and whether it can be effective as a monotherapy in

advanced disease, or as part of multi-modality prostate cancer therapy. To address these

questions we have started the phase I/II trial ADVANCE, which is currently recruiting patients

with intermediate-risk prostate cancer, and patients with advanced mCRPC, to receive

ChAdOx1-MVA 5T4 vaccine in combination with nivolumab (NCT03815942).

Materials and Methods

Study design

VANCE was a phase I randomised open label study designed to assess the safety and

immunogenicity of ChAdOx1-MVA 5T4 vaccine with and without low dose

cyclophosphamide in low- and intermediate-risk localised prostate cancer. Participants were

enrolled at the Oxford University Hospitals NHS Foundation Trust, and the Sheffield Teaching

Hospitals NHS Foundation Trust, in the United Kingdom (UK). Written informed consent was

obtained from all participating patients, and the trial was conducted in accordance with the

principles of the Declaration of Helsinki and Good Clinical Practice. This study was approved

within the UK by the Medicines and Healthcare Products Regulatory Agency and the South

Centre Berkshire Research Ethics Committee.

The trial was registered with the U.S. National Institutes of Health (NIH) Clinical Trials

Registry (ClinicalTrials.gov identifier NCT02390063).

The sample size was chosen to allow an initial descriptive report of the safety and

immunogenicity of the vaccine in a first-in-human trial.

Randomization was performed by an independent statistician at the Centre for Statistics in

Medicine, Oxford University. Allocation was performed using a balanced-block stratified

randomization.

Study population

The target population for this study was men newly diagnosed with low- or intermediate-risk

prostate cancer who had chosen radical prostatectomy as their treatment option, and men with

low-volume low-risk prostate cancer on an active surveillance programme (AS) and stable for

at least a year. Patients eligible for the study had histologically confirmed prostate cancer, PSA

≤ 20 ng/ml, Gleason score ≤ 7, clinical stage disease $\leq$ T2c, and no evidence of metastases.

Exclusion criteria included history of immunodeficiency disease, systemic

immunosuppression, allergic response to previous vaccinia virus vaccinations, seropositivity

for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) or HIV.

Study products

Design and construction of ChAdOx1.5T4 vaccine has been described previously (*15*).

ChAdOx1.5T4 was manufactured to clinical good manufacturing practice (cGMP) by the

Clinical Biomanufacturing Facility (University of Oxford, Oxford, UK) in the human

embryonic kidney 293 cell line. The vectored vaccine was purified by cesium chloride

isopycnic centrifugation and sterile filtered to generate a clinical lot at a concentration of

2.02×10^{11} vp per ml. The ChAdOx1.5T4 vaccine has been administered at the dose of 2.5 x

10^{10} vp. MVA.5T4 vaccine was manufactured and supplied for the trial by Oxford BioMedica

Ltd (TroVax®), and has been described previously (*43*). The MVA.5T4 vaccine has been

administered at the dose of 2.0 x 10^9 $TCID_{50}$ (equivalent to 1.2 x 10^8 pfu). Both vaccines were

administered by intramuscular injection in the thigh.

Cyclophosphamide (CTX) (manufactured by Baxter) was self-administered orally at 50mg

twice a day for a seven-day cycle before each vaccination.

Study procedures

Following screening, patients in the surgical arms were randomly allocated to 6 groups.

Participants in Groups 1 and 2 received one ChAdOx1.5T4 immunisation followed by two

MVA.5T4 boosts 4 weeks apart and underwent radical prostatectomy at week 12 post

enrolment. Participants in Groups 3 and 4 received three MVA.5T4 immunisations 4 weeks

apart and also underwent radical prostatectomy at week 12 post enrolment. This immunisation

schedule was termed a "standard" vaccination regimen. Participants in Groups 5 and 6 were

administered with ChAdOx1.5T4 vaccine followed by MVA.5T4 vaccination one week later

and underwent radical prostatectomy at week 4 post enrolment. This immunisation schedule

was termed an "accelerated" vaccination regimen. Patients on the active surveillance

programme were randomised to Groups 7 and 8 and received an accelerated vaccination

regimen followed by on-study prostate biopsy at week 10 post enrolment. The participants in

Groups 2, 4, 5 and 6 received an oral course of low dose CTX for 7 days prior to each

immunisation. The study treatment schedule is outlined in Supplementary Figure S1.

Blood samples were drawn and clinical assessments conducted for safety, immunology and

PSA monitoring prior to vaccination at day 0 and at each scheduled clinical time point

following enrolment. Solicited local site reactions and systemic symptoms were recorded by

participants using paper diaries during the 7-day follow-up period. Unsolicited AEs and SAEs

were recorded for 28 days. The severity of AEs was graded using the following criteria: a) mild

(short-lived or mild symptoms with no limitation to usual activity); b) moderate (mild to

moderate limitation in usual activity); and c) severe (considerable limitation in activity,

medication or medical attention required).

Fresh prostate tissue specimens were collected from surgical radical prostatectomy specimens,

and from on-study biopsies in active surveillance patients, for analysis of post-vaccination

immune cell subsets within the prostate tissue following treatment.

Endpoints

Primary objectives of the study were safety of ChAdOx1-MVA 5T4 vaccination and the

induction of immune responses to the vaccine encoded tumour-associated antigen 5T4 in the

blood following treatment. Secondary objectives of the study included comparative

immunogenicity assessment of the standard and accelerated vaccination regimens, the effect

of CTX pre-conditioning on the magnitude of immune responses, the effect of vaccination on

the immune cells in the tumour, and serum PSA change during the study.

Ex vivo IFN-γ ELISpot

Ex vivo IFN-γ ELISpot assay was performed at each time point in order to assess vaccine-

induced immune responses. Briefly, 2.5×10^5 freshly isolated PBMCs were plated in 96-well

PVDF plates pre-coated with anti-IFN-γ antibody, and stimulated with 8 individual pools each

consisting of 10-12 15mer peptides overlapping by 10 amino acids, spanning the complete 5T4

protein sequence. Unstimulated cells were used as a background control and Staphylococcus

enterotoxin B (SEB) and CMV/Epstein-Barr/Flu (CEF) peptide mix (Mabtech AB) were used

as positive controls. After 18-24 hours incubation, plates were developed and the number of

IFN-γ producing cells (SFCs) was evaluated using an automated ELISpot reader (AID). 5T4-

specific response was deemed to be positive at any time point when the mean number of SFCs

per one million PBMCs was at least 40, and the number of spots per well at least two times the

background. If a pre-existing T cell response was detected, a positive response due to

vaccination was reported if the post immunisation response was ≥2-fold the response

determined before immunization. Positive responses to individual pools were summed to give

final SFCs values per million PBMCs.

In vitro culture of PBMCs and TILs

PBMCs and TILs were cultured *in vitro* to expand 5T4-specific T cells. Briefly, 3×10^6 freshly

isolated PBMCs/ml were plated in complete medium with or without total 5T4 peptide pool

(5μg /ml) in the presence of recombinant human IL-7 (rhIL-7) (25ng/ml). Every 3-4 days the

medium was replaced and rhIL-2 (100U/ml) added to the cultures. PBMCs were harvested

after 2 weeks and incubated overnight at 37 °C before further analysis. To obtain TIL cultures,

radical prostatectomy specimen tissue cores and prostate biopsies were cut into small pieces

and cultured in the presence of rhIL-2 (6000U/ml) as described previously (*44*). TIL medium

was replaced every 2-3 days and the total 5T4 peptide pool was added when immune cell

cultures entered an exponential growth phase. TILs were typically harvested 1-week post 5T4

stimulation for further analysis.

Flow cytometric analysis

In vitro cultured PBMCs and TILs were incubated with 1μg/ml of co-stimulatory antibodies

αCD28/αCD49d (eBioscience) followed by stimulation in 96 well plates with complete

medium, SEB (1μg/ml) or total 5T4 peptide pool (5μg/ml). Following a 2-hour incubation,

brefeldin A and monensin (BD Bioscience) was added and cells were incubated overnight at

37 °C. PBMCs were stained with surface antibodies, fixed and permeabilized, and incubated

with intracellular antibodies (Supplementary Table S5). Dead cells were discriminated by

live/dead fixable staining (Life technologies). Samples were acquired on an LSRII flow

cytometer and analyzed with FlowJo software.

Patients were deemed to be "responders" when the percentages of IFN-γ+TNF-α+ CD4+ and

CD8+ T cells after stimulation were higher than 0.02 and were at least 2-fold the background

upon analysis in at least one time point post-vaccination. In addition, for cultured PBMCs the

delta values (5T4 value – background value) had to be equal/greater than 2-fold the

corresponding baseline (BL) delta value.

Tissue biopsy evaluation

Archival diagnostic biopsies from active surveillance patients collected within one year prior

to enrolment, and on-study template or targeted biopsies obtained at week 10 post enrolment,

were evaluated. Tissue sections were stained immunohistochemically for expression of CD3

(clone LN10, Leica) and CD8 (clone C8/144B, Dako) at the ISO 15189 accredited NHS

Cellular Pathology Laboratory at Oxford University Hospitals NHS Foundation Trust (Oxford,

UK). CD3+ and CD8+ T cells were enumerated according to the Tissue Phenomics approach

employing a visual context random forest algorithm (45) by Definiens GmbH (Munich,

Germany). Epithelial and stromal regions were segmented via an in-house, pre-trained

convolutional neural network (46), and cell densities were calculated as the number of marker

positive cells per reference area (mm2).

Data presentation and statistical analysis

Safety data is presented according to the frequency, severity and duration of solicited local and

systemic reactogenicity signs and symptoms for seven days following vaccination. Unsolicited

AEs and SAEs were recorded for four weeks post vaccination. Statistical analysis of

immunogenicity data was conducted using GraphPad Prism version 8 (GraphPad Software

Inc., San Diego, CA, USA). Comparisons between datasets were performed using non-

parametric tests, as detailed in the figure legends. All *P* values are two-sided and considered

statistically significant if $P < 0.05$.

Supplementary Materials

Materials and methods

Fig. S1. VANCE study design.

Fig. S2. Correlation analysis of vaccination induced T cell and antibody responses.

Fig. S3. T cell infiltration in the prostate gland of vaccinated active surveillance patients

Table S1. Baseline demographics and disease characteristics of VANCE study.

Table S2. 5T4- and MVA-specific antibody responses in plasma of vaccinated patients.

Table S3. *Ex vivo* IFN-γ ELISpot results on frozen PBMCs depleted of CD4+ or CD8+ T cells.

Table S4. T cell density in the prostate gland of vaccinated surgical patients measured by IHC.

Table S5. Antibody panel for flow cytometry staining of stimulated cultured PBMCs and TILs.

References:

1.   M. B. Culp, I. Soerjomataram, J. A. Efstathiou, F. Bray, A. Jemal, Recent Global

Patterns in Prostate Cancer Incidence and Mortality Rates. *European urology* **77**, 38-

52 (2020).

2.   H. C. Kantoff PW, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari

AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, IMPACT Study

Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N*

Engl J Med. **363**, 411-422. (2010).

3.   N. A. Sheikh *et al.*, Sipuleucel-T immune parameters correlate with survival: an

analysis of the randomized phase 3 clinical trials in men with castration-resistant

prostate cancer. *Cancer immunology, immunotherapy : CII* **62**, 137-147 (2013).

4.   J. L. Gulley *et al.*, Immune Impact Induced by PROSTVAC (PSA-TRICOM), a

Therapeutic Vaccine for Prostate Cancer. *Cancer Immunology Research* **2**, 133141

(2013).

5.   J. L. Gulley *et al.*, Phase III Trial of PROSTVAC in Asymptomatic or Minimally

Symptomatic Metastatic Castration-Resistant Prostate Cancer. *Journal of clinical*

oncology : official journal of the American Society of Clinical Oncology **37**, 1051-

1061 (2019).

6.   P. J. Southall *et al.*, Immunohistological distribution of 5T4 antigen in normal and

malignant tissues. *British Journal of Cancer* **61**, 89-95 (1990).

7.   K. J. Ewer *et al.*, Protective CD8+ T-cell immunity to human malaria induced by

chimpanzee adenovirus-MVA immunisation. *Nat Commun* **4**, 2836 (2013).

8.   R. D. Antrobus *et al.*, Clinical assessment of a novel recombinant simian adenovirus

ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.

Molecular therapy : the journal of the American Society of Gene Therapy **22**, 668-674

(2014).

9.   N. Borthwick *et al.*, Vaccine-elicited human T cells recognizing conserved protein

regions inhibit HIV-1. *Molecular therapy : the journal of the American Society of*

Gene Therapy **22**, 464-475 (2014).

10.   L. Swadling *et al.*, A human vaccine strategy based on chimpanzee adenoviral and

MVA vectors that primes, boosts, and sustains functional HCV-specific T cell

memory. *Science translational medicine* **6**, 261ra153 (2014).

11.   K. Ewer *et al.*, A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with

692   MVA. *The New England journal of medicine* **374**, 1635-1646 (2016).

693   12.   A. B. Tiono *et al.*, First field efficacy trial of the ChAd63 MVA ME-TRAP vectored

694   malaria vaccine candidate in 5-17 months old infants and children. *PloS one* **13**,

695   e0208328 (2018).

696   13.   N. Venkatraman *et al.*, Safety and Immunogenicity of a Heterologous Prime-Boost

697   Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal.

698   *The Journal of infectious diseases* **219**, 1187-1197 (2019).

699   14.   F. Cappuccini, S. Stribbling, E. Pollock, A. V. Hill, I. Redchenko, Immunogenicity

700   and efficacy of the novel cancer vaccine based on simian adenovirus and MVA

701   vectors alone and in combination with PD-1 mAb in a mouse model of prostate

702   cancer. *Cancer immunology, immunotherapy : CII* **65**, 701-713 (2016).

703   15.   F. Cappuccini, E. Pollock, S. Stribbling, A. V. S. Hill, I. Redchenko, 5T4 oncofoetal

704   glycoprotein: an old target for a novel prostate cancer immunotherapy. *Oncotarget*,

705   (2017).

706   16.   S. J. McConkey *et al.*, Enhanced T-cell immunogenicity of plasmid DNA vaccines

707   boosted by recombinant modified vaccinia virus Ankara in humans. *Nat Med* **9**, 729-

708   735 (2003).

709   17.   M. O. Afolabi *et al.*, A phase I randomized clinical trial of candidate human

710   immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian

711   infants. *PloS one* **8**, e78289 (2013).

712   18.   R. Harrop *et al.*, MVA-5T4-induced immune responses are an early marker of

713   efficacy in renal cancer patients. *Cancer immunology, immunotherapy : CII* **60**, 829-

714   837 (2011).

19.   P. S. Gill *et al.*, The handling and sampling of radical prostatectomy specimens for
reporting and research: the Oxford approach. *J Clin Pathol* **65**, 1057-1061 (2012).

20.   N. Harder *et al.*, Tissue Phenomics for prognostic biomarker discovery in low- and
intermediate-risk prostate cancer. *Sci Rep* **8**, 4470 (2018).

21.   P. F. Schellhammer *et al.*, Lower baseline prostate-specific antigen is associated with
a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate
Adenocarcinoma Treatment (IMPACT) trial. *Urology* **81**, 1297-1302 (2013).

22.   D. N. Amato RJ, Naylor S et al. , Vaccination of Prostate Cancer Patients With
Modified Vaccinia Ankara Delivering the Tumour Antigen 5T4 (TroVax): A Phase 2
Trial. . *Journal of immunotherapy* **31**, 577-585 (2008).

23.   L. Coughlan *et al.*, Heterologous Two-Dose Vaccination with Simian Adenovirus and
Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in
Healthy Adults. *EBioMedicine* **29**, 146-154 (2018).

24.   D. G. McNeel *et al.*, Safety and immunological efficacy of a DNA vaccine encoding
prostatic acid phosphatase in patients with stage D0 prostate cancer. *Journal of
clinical oncology : official journal of the American Society of Clinical Oncology* **27**,
4047-4054 (2009).

25.   J. T. Becker *et al.*, DNA vaccine encoding prostatic acid phosphatase (PAP) elicits
long-term T-cell responses in patients with recurrent prostate cancer. *Journal of
immunotherapy* **33**, 639-647 (2010).

26.   D. G. McNeel *et al.*, Concurrent, but not sequential, PD-1 blockade with a DNA
vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant
prostate cancer. *Oncotarget* **9**, 25586-25596 (2018).

27.   H. Kubler *et al.*, Self-adjuvanted mRNA vaccination in advanced prostate cancer
patients: a first-in-man phase I/IIa study. *J Immunother Cancer* **3**, 26 (2015).

28. D. T. Le, E. M. Jaffee, Regulatory T-cell modulation using cyclophosphamide in

vaccine approaches: a current perspective. *Cancer research* **72**, 3439-3444 (2012).

29. M. Scurr *et al.*, Effect of Modified Vaccinia Ankara–5T4 and Low-Dose

Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A

Randomized Clinical Trial. *JAMA Oncology*, (2017).

30. L. Fong *et al.*, Activated lymphocyte recruitment into the tumor microenvironment

following preoperative sipuleucel-T for localized prostate cancer. *J Natl Cancer Inst*

106, (2014).

31. B. Farsaci *et al.*, Identification by digital immunohistochemistry of intratumoral

changes of immune infiltrates after vaccine in the absence of modifications of PBMC

immune cell subsets. *International journal of cancer. Journal international du cancer*

135, 862-870 (2014).

32. M. Mercader *et al.*, T cell infiltration of the prostate induced by androgen withdrawal

in patients with prostate cancer. *Proc Natl Acad Sci U S A* **98**, 14565-14570 (2001).

33. A. Strasner, M. Karin, Immune Infiltration and Prostate Cancer. *Front Oncol* **5**, 128

(2015).

34. S. Vesalainen, P. Lipponen, M. Talja, K. Syrjanen, Histological grade, perineural

infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-

term prognosis in prostatic adenocarcinoma. *Eur J Cancer* **30A**, 1797-1803 (1994).

35. J. Irani *et al.*, High-grade inflammation in prostate cancer as a prognostic factor for

biochemical recurrence after radical prostatectomy. Pathologist Multi Center Study

Group. *Urology* **54**, 467-472 (1999).

36. P. A. McArdle *et al.*, The relationship between T-lymphocyte subset infiltration and

survival in patients with prostate cancer. *Br J Cancer* **91**, 541-543 (2004).

37.   V. Karja *et al.*, Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free

survival in patients with local prostate carcinoma treated by radical prostatectomy.

Anticancer Res **25**, 4435-4438 (2005).

38.   S. G. Zhao *et al.*, The Immune Landscape of Prostate Cancer and Nomination of PD-

L2 as a Potential Therapeutic Target. *J Natl Cancer Inst* **111**, 301-310 (2019).

39.   M. A. McNamara, D. J. George, Pain, PSA flare, and bone scan response in a patient

with metastatic castration-resistant prostate cancer treated with radium-223, a case

report. *BMC cancer* **15**, 371 (2015).

40.   F. H. Karzai, R. A. Madan, W. D. Figg, Beyond PSA: managing modern therapeutic

options in metastatic castration-resistant prostate cancer. *South Med J* **108**, 224-228

(2015).

41.   Y. Yamamoto *et al.*, Tumour and immune cell dynamics explain the PSA bounce

after prostate cancer brachytherapy. *Br J Cancer* **115**, 195-202 (2016).

42.   F. S. Hodi *et al.*, Immune-Modified Response Evaluation Criteria In Solid Tumors

(imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer

Immunotherapy. *Journal of clinical oncology : official journal of the American

Society of Clinical Oncology* **36**, 850-858 (2018).

43.   K. Kim, Bines and Kaufman, Trovax, a recombinant modified vaccinia ankara virus

encoding 5T4. Lessons learned and future development. *Human Vaccines* **6**, 784-791

(2010).

44.   L. T. Nguyen *et al.*, Expansion and characterization of human melanoma tumor-

infiltrating lymphocytes (TILs). *PloS one* **5**, e13940 (2010).

45.   N. Brieu, O. Pauly, J. Zimmermann, G. Binnig, G. Schmidt, *Slide-specific models for

segmentation of differently stained digital histopathology whole slide images*. SPIE

Medical Imaging (SPIE, 2016), vol. 9784.

46.   A. Kapil *et al.*, Deep Semi Supervised Generative Learning for Automated Tumor

790   Proportion Scoring on NSCLC Tissue Needle Biopsies. *Sci Rep* **8**, 17343 (2018).

Acknowledgments:

We thank the trial participants and their families for their involvement in this study, the study

teams at the local sites for assistance in the execution of this clinical trial, the Oxford Centre

for Histopathology Research for processing samples for IHC. We acknowledge support of

Clare Verrill by the NIHR Oxford Biomedical Research Centre. We are grateful to Oxford

Biomedica Ltd for supplying the MVA.5T4 vaccine.

Author contributions:

Trial conception and design: FH, AVSH, IR

Experimental design, data analysis and interpretation: FC, AH, IR

Laboratory data generation: FC, EP, AM, GS, RH, SV

Provision of patients: RB, LC, JH, JC, FH

Collection of biological samples or clinical data: CV, IP, MB, CM, AP, RM, SK, SM

Protocol development: RB, LC, PR, TE, FH, AVSH, IR

Administrative support: AB

Manuscript writing: FC, IR

Manuscript review: RB, CV, AM, GS, RH, SV, PR, TE, JC, FH, AVSH

Final approval of manuscript: All authors